within Pharmacolibrary.Drugs.ATC.R;

model R03AC13
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0025666666666666667,
    adminDuration  = 600,
    adminMass      = 12 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.279,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.309,
    k12             = 142,
    k21             = 142
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03AC13</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Formoterol is a long-acting beta2-adrenergic agonist (LABA) used primarily as a bronchodilator for the management of asthma and chronic obstructive pulmonary disease (COPD). It is usually administered via inhalation and is approved for use in many countries worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following single inhaled dose.</p><h4>References</h4><ol><li><p>Rony, F, et al., &amp; Klein, J (2024). Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant. <i>Pulmonary pharmacology &amp; therapeutics</i> 85 102299–None. DOI:<a href=\"https://doi.org/10.1016/j.pupt.2024.102299\">10.1016/j.pupt.2024.102299</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38663512/\">https://pubmed.ncbi.nlm.nih.gov/38663512</a></p></li><li><p> (2020). Drugs for COPD. <i>The Medical letter on drugs and therapeutics</i> 62(1606) 137–144. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32960872/\">https://pubmed.ncbi.nlm.nih.gov/32960872</a></p></li><li><p>Lecaillon, JB, et al., &amp; Della Cioppa, G (1999). Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. <i>European journal of clinical pharmacology</i> 55(2) 131–138. DOI:<a href=\"https://doi.org/10.1007/s002280050607\">10.1007/s002280050607</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10335908/\">https://pubmed.ncbi.nlm.nih.gov/10335908</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03AC13;
